752 related articles for article (PubMed ID: 33449302)
21. Potential angiogenic, immunomodulatory, and antifibrotic effects of mesenchymal stem cell-derived extracellular vesicles in systemic sclerosis.
Zhao K; Kong C; Shi N; Jiang J; Li P
Front Immunol; 2023; 14():1125257. PubMed ID: 37251412
[TBL] [Abstract][Full Text] [Related]
22. Scleroderma epidemiology update.
Calderon LM; Pope JE
Curr Opin Rheumatol; 2021 Mar; 33(2):122-127. PubMed ID: 33481429
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status.
Burt RK; Milanetti F
Curr Opin Rheumatol; 2011 Nov; 23(6):519-29. PubMed ID: 21857226
[TBL] [Abstract][Full Text] [Related]
24. Atypical Scleroderma-like Chronic GVHD in a Liver Transplant Patient, Clinical and MRI Correlations.
Giannoni M; Rizzetto G; Diotallevi F; Molinelli E; Radi G; Campanati A; Brancorsni D; Offidani A
Acta Dermatovenerol Croat; 2022 Sep; 30(2):123-125. PubMed ID: 36254548
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of systemic sclerosis-associated interstitial lung disease].
Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
[TBL] [Abstract][Full Text] [Related]
26. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
Jimenez SA; Piera-Velazquez S
Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.
Binks M; Passweg JR; Furst D; McSweeney P; Sullivan K; Besenthal C; Finke J; Peter HH; van Laar J; Breedveld FC; Fibbe WE; Farge D; Gluckman E; Locatelli F; Martini A; van den Hoogen F; van de Putte L; Schattenberg AV; Arnold R; Bacon PA; Emery P; Espigado I; Hertenstein B; Hiepe F; Kashyap A; Kötter I; Marmont A; Martinez A; Pascual MJ; Gratwohl A; Prentice HG; Black C; Tyndall A
Ann Rheum Dis; 2001 Jun; 60(6):577-84. PubMed ID: 11350846
[TBL] [Abstract][Full Text] [Related]
28. Major lung complications of systemic sclerosis.
Denton CP; Wells AU; Coghlan JG
Nat Rev Rheumatol; 2018 Sep; 14(9):511-527. PubMed ID: 30111804
[TBL] [Abstract][Full Text] [Related]
29. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis.
Jerjen R; Nikpour M; Krieg T; Denton CP; Saracino AM
J Am Acad Dermatol; 2022 Nov; 87(5):937-954. PubMed ID: 35131402
[TBL] [Abstract][Full Text] [Related]
30. Interstitial lung disease in systemic sclerosis: current and future treatment.
Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
[TBL] [Abstract][Full Text] [Related]
31. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis.
Badea I; Taylor M; Rosenberg A; Foldvari M
Rheumatology (Oxford); 2009 Mar; 48(3):213-21. PubMed ID: 19022832
[TBL] [Abstract][Full Text] [Related]
32. Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges.
Peltzer J; Aletti M; Frescaline N; Busson E; Lataillade JJ; Martinaud C
Front Immunol; 2018; 9():2013. PubMed ID: 30271402
[TBL] [Abstract][Full Text] [Related]
33. Treatment of scleroderma.
Sapadin AN; Fleischmajer R
Arch Dermatol; 2002 Jan; 138(1):99-105. PubMed ID: 11790173
[TBL] [Abstract][Full Text] [Related]
34. Targeting Costimulatory Pathways in Systemic Sclerosis.
Boleto G; Allanore Y; Avouac J
Front Immunol; 2018; 9():2998. PubMed ID: 30619351
[TBL] [Abstract][Full Text] [Related]
35. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review.
McGaugh S; Kallis P; De Benedetto A; Thomas RM
Dermatol Ther; 2022 Jun; 35(6):e15437. PubMed ID: 35278019
[TBL] [Abstract][Full Text] [Related]
36. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
Yoshizaki A
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
[TBL] [Abstract][Full Text] [Related]
37. Differentially expressed genes in systemic sclerosis: Towards predictive medicine with new molecular tools for clinicians.
Keret S; Rimar D; Lansiaux P; Feldman E; Lescoat A; Milman N; Farge D;
Autoimmun Rev; 2023 Jun; 22(6):103314. PubMed ID: 36918090
[TBL] [Abstract][Full Text] [Related]
38. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.
Lescoat A; Varga J; Matucci-Cerinic M; Khanna D
Expert Opin Investig Drugs; 2021 Jun; 30(6):635-652. PubMed ID: 33909517
[No Abstract] [Full Text] [Related]
39. Clinical and laboratory features of systemic sclerosis complicated with localized scleroderma.
Toki S; Motegi S; Yamada K; Uchiyama A; Kanai S; Yamanaka M; Ishikawa O
J Dermatol; 2015 Mar; 42(3):283-7. PubMed ID: 25582037
[TBL] [Abstract][Full Text] [Related]
40. Advances in biological and targeted therapies for systemic sclerosis.
Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
